Aetiology of Myeloproliferative Neoplasms
Abstract
:1. Introduction
2. Incidence and Prevalence of MPNs
3. Etiological Studies: Principles and Methods
3.1. Cohort Studies
3.2. Case-Control Studies
3.3. Ecological Studies
4. Genetic Factors in the Development of MPN
5. Epidemiological Studies in MPN
6. The MOSAICC Study
7. Other Findings from MOSAICC Study
8. The Way Forward
9. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Arber, D.A.; Orazi, A.; Hasserjian, R.; Thiele, J.; Borowitz, M.J.; Le Beau, M.M.; Bloomfield, C.D.; Cazzola, M.; Vardiman, J.W. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukaemia. Blood 2016, 127, 2391–2405. [Google Scholar] [CrossRef] [PubMed]
- James, C.; Ugo, V.; Casadevall, N.; Constantinescu, S.N.; Vainchenker, W. A JAK2 mutation in myeloproliferative disorders: Pathogenesis and therapeutic and scientific prospects. Trends. Mol. Med. 2005, 11, 546–554. [Google Scholar] [CrossRef] [PubMed]
- Pikman, Y.; Lee, B.H.; Mercher, T.; McDowell, E.; Ebert, B.L.; Gozo, M.; Cuker, A.; Wernig, G.; Moore, S.; Galinsky, I.; et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006, 3, e270. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nangalia, J.; Massie, C.E.; Baxter, E.J.; Nice, F.L.; Gundem, G.; Wedge, D.C.; Avezov, E.; Li, J.; Kollmann, K.; Kent, D.G.; et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N. Engl. J. Med. 2013, 369, 2391–2405. [Google Scholar] [CrossRef] [Green Version]
- Hultcrantz, M.; Kristinsson, S.Y.; Andersson, T.M.; Landgren, O.; Eloranta, S.; Derolf, A.R.; Dickman, P.W.; Björkholm, M. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: A population-based study. J. Clin. Oncol. 2012, 30, 2995–3001. [Google Scholar] [CrossRef] [Green Version]
- rarecarenet.eu Rarecarenet.eu. Available online: http://www.rarecarenet.eu (accessed on 5 July 2020).
- Marchetti, M.; Ghirardi, A.; Masciulli, A.; Carobbio, A.; Palandri, F.; Vianelli, N.; Rossi, E.; Betti, S.; Di Veroli, A.; Iurlo, A.; et al. Second cancers in MPN: Survival analysis from an international study. Am. J. Haematol. 2020, 95, 295–301. [Google Scholar] [CrossRef] [PubMed]
- Hultcrantz, M.; Wilkes, S.R.; Kristinsson, S.Y.; Andersson, T.M.; Derolf, Å.; Eloranta, S.; Samuelsson, J.; Landgren, O.; Dickman, P.W.; Lambert, P.C.; et al. Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study. J. Clin. Oncol. 2015, 33, 2288–2295. [Google Scholar] [CrossRef]
- Titmarsh, G.J.; Duncombe, A.S.; McMullin, M.F.; O’Rorke, M.; Mesa, R.; De Vocht, F.; Horan, S.; Fritschi, L.; Clarke, M.; Anderson, L.A. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am. J. Haematol. 2014, 89, 581–587. [Google Scholar] [CrossRef]
- Anderson, L.A.; Duncombe, A.S.; Hughes, M.; Mills, M.E.; Wilson, J.C.; McMullin, M.F. Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms. Am. J. Haematol. 2012, 87, 175–182. [Google Scholar] [CrossRef]
- Kurita, S. Epidemiological studies of polycythemia vera in Japan (author’s transl). Nihon Ketsueki Gakkai Zasshi 1974, 37, 793–795. [Google Scholar]
- Srour, S.A.; Devesa, S.S.; Morton, L.M.; Check, D.P.; Curtis, R.E.; Linet, M.S.; Dores, G.M. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001–2012. Br. J. Haematol. 2016, 174, 382–396. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Moulard, O.; Mehta, J.; Fryzek, J.; Olivares, R.; Iqbal, U.; Mesa, R.A. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur. J. Haematol. 2014, 92, 289–297. [Google Scholar] [CrossRef] [PubMed]
- Roaldsnes, C.; Holst, R.; Frederiksen, H.; Ghanima, W. Myeloproliferative neoplasms: Trends in incidence, prevalence and survival in Norway. Eur. J. Haematol. 2017, 98, 85–93. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hultcrantz, M.; Ravn Landtblom, A.; Andréasson, B.; Samuelsson, J.; Dickman, P.W.; Kristinsson, S.Y.; Björkholm, M.; Andersson, T.M. Incidence of myeloproliferative neoplasms—Trends by subgroup and age in a population-based study in Sweden. J. Intern. Med. 2020, 287, 448–454. [Google Scholar] [CrossRef]
- Baade, P.D.; Ross, D.M.; Anderson, L.A.; Forsyth, C.; Fritschi, L. Changing incidence of myeloproliferative neoplasms in Australia, 2003–2014. Am. J. Haematol. 2019, 94, E107–E109. [Google Scholar] [CrossRef] [Green Version]
- Byun, J.M.; Kim, Y.J.; Youk, T.; Yang, J.J.; Yoo, J.; Park, T.S. Real world epidemiology of myeloproliferative neoplasms: A population based study in Korea 2004–2013. Ann. Haematol. 2017, 96, 373–381. [Google Scholar] [CrossRef]
- Xu, X.; Zhang, Q.; Luo, J.; Xing, S.; Li, Q.; Krantz, S.B.; Fu, X.; Zhao, Z.J. JAK2(V617F): Prevalence in a large Chinese hospital population. Blood 2007, 109, 339–342. [Google Scholar] [CrossRef] [Green Version]
- Cordua, S.; Kjaer, L.; Skov, V.; Pallisgaard, N.; Hasselbalch, H.C.; Ellervik, C. Prevalence and phenotypes of JAK2V617F and calreticulin mutations in the Danish general population. Blood 2019, 134, 469–479. [Google Scholar] [CrossRef]
- Ghilardi, N.; Wiestner, A.; Kikuchi, M.; Ohsaka, A.; Skoda, R.C. Hereditary thrombocythaemia in a Japanese family is caused by a novel point mutation in the thrombopoietin gene. Br. J. Haematol. 1999, 107, 310–316. [Google Scholar] [CrossRef]
- Percy, M.J.; McMullin, M.F.; Roques, A.W.; Westwood, N.B.; Acharya, J.; Hughes, A.E.; Lappin, T.R.; Pearson, T.C. Erythrocytosis due to a mutation in the erythropoietin receptor gene. Br. J. Haematol. 1998, 100, 407–410. [Google Scholar] [CrossRef]
- Rumi, E.; Passamonti, F.; Della Porta, M.G.; Elena, C.; Arcaini, L.; Vanelli, L.; Del Curto, C.; Pietra, D.; Boveri, E.; Pascutto, C.; et al. Familial chronic myeloproliferative disorders: Clinical phenotype and evidence of disease anticipation. J. Clin. Oncol. 2007, 25, 5630–5635. [Google Scholar] [CrossRef]
- Jones, A.V.; Chase, A.; Silver, R.T.; Oscier, D.; Zoi, K.; Wang, Y.L.; Cario, H.; Pahl, H.L.; Collins, A.; Reiter, A.; et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat. Genet. 2009, 41, 446–449. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Saliba, J.; Saint-Martin, C.; Di Stefano, A.; Lenglet, G.; Marty, C.; Keren, B.; Pasquier, F.; Valle, V.D.; Secardin, L.; Leroy, G.; et al. Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies. Nat. Genet. 2015, 47, 1131–1140. [Google Scholar] [CrossRef]
- Oddsson, A.; Kristinsson, S.Y.; Helgason, H.; Gudbjartsson, D.F.; Masson, G.; Sigurdsson, A.; Jonasdottir, A.; Steingrimsdottir, H.; Vidarsson, B.; Reykdal, S. The germline sequence variant rs2736100_C in TERT associates with myeloproliferative neoplasms. Leukaemia 2014, 28, 1371–1374. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jäger, R.; Harutyunyan, A.S.; Rumi, E.; Pietra, D.; Berg, T.; Olcaydu, D.; Houlston, R.S.; Cazzola, M.; Kralovics, R. Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms. Am. J. Haematol. 2014, 89, 1107–1110. [Google Scholar] [CrossRef] [Green Version]
- Harutyunyan, A.S.; Giambruno, R.; Krendl, C.; Stukalov, A.; Klampfl, T.; Berg, T.; Chen, D.; Milosevic Feenstra, J.D.; Jäger, R.; Gisslinger, B.; et al. Germline RBBP6 mutations in familial myeloproliferative neoplasms. Blood 2016, 127, 362–365. [Google Scholar] [CrossRef] [Green Version]
- Trifa, A.P.; Bănescu, C.; Bojan, A.S.; Voina, C.M.; Popa, Ș.; Vișan, S.; Ciubean, A.D.; Tripon, F.; Dima, D.; Popov, V.M.; et al. MECOM, HBS1L-MYB, THRB-RARB, JAK2, and TERT polymorphisms defining the genetic predisposition to myeloproliferative neoplasms: A study on 939 patients. Am. J. Haematol. 2018, 93, 100–106. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hirvonen, E.A.M.; Pitkänen, E.; Hemminki, K.; Aaltonen, L.A.; Kilpivaara, O. Whole-exome sequencing identifies novel candidate predisposition genes for familial polycythemia vera. Hum. Genom. 2017, 11, 6. [Google Scholar] [CrossRef] [PubMed]
- Tapper, W.; Jones, A.V.; Kralovics, R.; Harutyunyan, A.S.; Zoi, K.; Leung, W.; Godfrey, A.L.; Guglielmelli, P.; Callaway, A.; Ward, D.; et al. Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. Nat. Commun. 2015, 6, 6691. [Google Scholar] [CrossRef] [Green Version]
- Hinds, D.A.; Barnholt, K.E.; Mesa, R.A.; Kiefer, A.K.; Do, C.B.; Eriksson, N.; Mountain, J.L.; Francke, U.; Tung, J.Y.; Nguyen, H.M.; et al. Germ line variants predispose to both JAK2 V617F clonal haematopoiesis and myeloproliferative neoplasms. Blood 2016, 128, 1121–1128. [Google Scholar] [CrossRef] [Green Version]
- Najean, Y.; Rain, J.D.; Billotey, C. Epidemiological data in polycythaemia vera: A study of 842 cases. Haematol. Cell Ther. 1998, 40, 159–165. [Google Scholar]
- Chaiter, Y.; Brenner, B.; Aghai, E.; Tatarsky, I. High incidence of myeloproliferative disorders in Ashkenazi Jews in northern Israel. Leuk. Lymphoma 1992, 7, 251–255. [Google Scholar] [CrossRef] [PubMed]
- Kaplan, S.D. Update of a mortality study of workers in petroleum refineries. J. Occup. Med. 1986, 28, 514–516. [Google Scholar] [CrossRef] [PubMed]
- Quiroga Micheo, E.; Calcagno, E.J.; Calabria, S.I.; Besuschio, S.C.; Magnasco, J.H.; Sackmann Muriel, F.; Maccione, E.; Barros, C.; Santoro, A.; de Soto, Z.C. Retrospective epidemiological study of hemopoietic system neoplasms in Argentina. Medicina (B. Aires) 1981, 41, 187–200. [Google Scholar] [PubMed]
- Mele, A.; Visani, G.; Pulsoni, A.; Monarca, B.; Castelli, G.; Stazi, M.A.; Gentile, G.; Mandelli, F. Risk factors for essential thrombocythemia: A case-control study. Italian Leukaemia Study Group. Cancer 1996, 77, 2157–2161. [Google Scholar] [CrossRef]
- Lickiss, J.N.; Giles, G.G.; Baikie, M.J.; Lowenthal, R.M.; Challis, D.; Panton, J. Myeloproliferative and lymphoproliferative disorders in Tasmania, 1972–1980: Patterns in space and time. J. Natl. Cancer Inst. 1984, 72, 1223–1231. [Google Scholar]
- Anderson, L.A.; Pfeiffer, R.M.; Landgren, O.; Gadalla, S.; Berndt, S.I.; Engels, E.A. Risks of myeloid malignancies in patients with autoimmune conditions. Br. J. Cancer 2009, 100, 822–828. [Google Scholar] [CrossRef] [Green Version]
- Kristinsson, S.Y.; Landgren, O.; Samuelsson, J.; Björkholm, M.; Goldin, L.R. Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica 2010, 95, 1216–1220. [Google Scholar] [CrossRef] [Green Version]
- Merk, K.; Mattsson, B.; Mattsson, A.; Holm, G.; Gullbring, B.; Björkholm, M. The incidence of cancer among blood donors. Int. J. Epidemiol. 1990, 19, 505–509. [Google Scholar] [CrossRef]
- Kroll, M.E.; Murphy, F.; Pirie, K.; Reeves, G.K.; Green, J.; Beral, V.; Million Women Study Collaborators. Alcohol drinking, tobacco smoking and subtypes of haematological malignancy in the UK Million Women Study. Br. J. Cancer 2012, 107, 879–887. [Google Scholar] [CrossRef] [Green Version]
- Murphy, F.; Kroll, M.E.; Pirie, K.; Reeves, G.; Green, J.; Beral, V. Body size in relation to incidence of subtypes of haematological malignancy in the prospective Million Women Study. Br. J. Cancer 2013, 108, 2390–2398. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Poluben, L.; Puligandla, M.; Neuberg, D.; Bryke, C.R.; Hsu, Y.; Shumeiko, O.; Yuan, X.; Voznesensky, O.; Pihan, G.; Adam, M.; et al. Characteristics of myeloproliferative neoplasms in patients exposed to ionizing radiation following the Chernobyl nuclear accident. Am. J. Haematol. 2019, 94, 62–73. [Google Scholar] [CrossRef] [Green Version]
- Edgren, G.; Nyrén, O.; Hultcrantz, M.; Nielsen, K.R.; Pedersen, O.B.; Björkholm, M.; Rostgaard, K.; Hjalgrim, H. Blood donation and risk of polycythemia vera. Transfusion 2016, 56, 1622–1627. [Google Scholar] [CrossRef]
- Leal, A.D.; Thompson, C.A.; Wang, A.H.; Vierkant, R.A.; Habermann, T.M.; Ross, J.A.; Mesa, R.A.; Virnig, B.A.; Cerhan, J.R. Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women’s Health Study cohort. Int. J. Cancer 2014, 134, 1741–1750. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jayasuriya, N.A.; Kjaergaard, A.D.; Pedersen, K.M.; Sørensen, A.L.; Bak, M.; Larsen, M.K.; Nordestgaard, B.G.; Bojesen, S.E.; Çolak, Y.; Skov, V.; et al. Smoking, blood cells and myeloproliferative neoplasms: Meta-analysis and Mendelian randomization of 2·3 million people. Br. J. Haematol. 2020, 189, 323–334. [Google Scholar] [CrossRef] [PubMed]
- Podoltsev, N.A.; Wang, X.; Wang, R.; Hofmann, J.N.; Liao, L.M.; Zeidan, A.M.; Mesa, R.; Ma, X. Lifestyle factors and risk of myeloproliferative neoplasms in the NIH-AARP diet and health study. Int. J. Cancer 2020, 147, 948–957. [Google Scholar] [CrossRef] [PubMed]
- Duncombe, A.S.; Anderson, L.A.; James, G.; de Vocht, F.; Fritschi, L.; Mesa, R.; Clarke, M.; McMullin, M.F. Modifiable Lifestyle and Medical Risk Factors Associated With Myeloproliferative Neoplasms. Haemasphere 2020, 4, e327. [Google Scholar] [CrossRef] [PubMed]
- James, G.; McMullin, M.F.; Duncombe, A.S.; Clarke, M.; Anderson, L.A. The MOSAICC study: Assessing feasibility for biological sample collection in epidemiology studies and comparison of DNA yields from saliva and whole blood samples. Ann. Hum. Genet. 2018, 82, 114–118. [Google Scholar] [CrossRef]
- Scherber, R.; Dueck, A.C.; Johansson, P.; Barbui, T.; Barosi, G.; Vannucchi, A.M.; Passamonti, F.; Andreasson, B.; Ferarri, M.L.; Rambaldi, A.; et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International prospective validation and reliability trial in 402 patients. Blood 2011, 118, 401–408. [Google Scholar] [CrossRef]
- Anderson, L.A.; James, G.; Duncombe, A.S.; Mesa, R.; Scherber, R.; Dueck, A.C.; de Vocht, F.; Clarke, M.; McMullin, M.F. Myeloproliferative neoplasm patient symptom burden and quality of life: Evidence of significant impairment compared to controls. Am. J. Haematol. 2015, 90, 864–870. [Google Scholar] [CrossRef] [Green Version]
- McMullin, M.F.; James, G.; Duncombe, A.S.; de Vocht, F.; Fritschi, L.; Clarke, M.; Anderson, L.A. Patient perspectives of a diagnosis of myeloproliferative neoplasm in a case control study. Exp. Haematol. Oncol. 2015, 5, 14. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Population Predisposition | Germline Variants in Families |
---|---|
JAK2 46/1 haplotype rs59384377 [23] | Germline duplication of ATG2B and GSKIP [24] |
TERT gene germline variant rs2736100_C) [25,26] | RBBP6-R1569H [27] |
Polymorphisms: MECOM rs2201862, HBS1L-MYB rs9376092, and THRB-RARB rs4858647 [28] | Novel variants in LRRC3 and BCORL1 [29] |
Factor | Significant Associations [10] |
---|---|
Family history | Relatives with female probands |
Jewish decent | Ashkenazi Jewish descent [32,33] |
Occupation | Poultry workers |
Commercial pressmen | |
Petroleum refinery workers [34,35] | |
Agricultural workers | |
Rural sector workers | |
Cooks and waiters | |
Clerks | |
Working with electrical devices | |
Chemical exposure | Benzene |
Petroleum | |
Dark hair dye use for more than 10 years and ET [36] | |
Residence | Rural residence [37] |
Tuff house and ET [36] | |
Medical conditions | Crohn’s disease [38] |
Giant cell arteritis [39] | |
Blood donation | Southern Stockholm [40] France |
Smoking | Increased risk of MPN in smokers compared to never smokers [41] |
Body mass index | Increased risk of MPN with each 10 kg/m2 increase in body mass index [42] |
Ionising radiation | Different pattern of driver mutations in those exposed to ionising radiation at Chernobyl [43] |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
McMullin, M.F.; Anderson, L.A. Aetiology of Myeloproliferative Neoplasms. Cancers 2020, 12, 1810. https://doi.org/10.3390/cancers12071810
McMullin MF, Anderson LA. Aetiology of Myeloproliferative Neoplasms. Cancers. 2020; 12(7):1810. https://doi.org/10.3390/cancers12071810
Chicago/Turabian StyleMcMullin, Mary Frances, and Lesley Ann Anderson. 2020. "Aetiology of Myeloproliferative Neoplasms" Cancers 12, no. 7: 1810. https://doi.org/10.3390/cancers12071810